Andere talen Viracta Therapeutics, Inc.

Aandelen

VIRX

US92765F1084

Vertraagde tijd Nasdaq Andere beurzen 16:05:52 28-06-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
0,6 ^USD	+3,80%		-4,03%	+5,26%

30/05	Day One Biopharmaceuticals verkoopt prioriteitsbeoordelingsvoucher voor $108 miljoen	MT
24/05	VIRACTA THERAPEUTICS, INC. : Oppenheimer herhaalt koopadvies	ZM

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

XOMA Receives $8.1 Million Milestone Related to Day One Biopharmaceuticals Sale of its Priority Review Voucher	13/06
XOMA Receives $8.1 Million Milestone Related to Sale of Priority Review Voucher	12/06
Day One Biopharmaceuticals Sells Priority Review Voucher for $108 Million	30/05
Viracta Therapeutics Announces New Employment Inducement Grants	17/05
Viracta Therapeutics Appoints Michael Faerm CFO	14/05
Viracta Therapeutics Appoints Michael Faerm as Chief Financial Officer	14/05
Viracta Therapeutics, Inc. Appoints Michael Faerm as Chief Financial Officer	14/05
Sunesis: Q1 Earnings Snapshot	09/05
Viracta Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	09/05
Viracta Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update	09/05
Viracta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference	07/05
Viracta Therapeutics Announces Positive Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial in Patients with Relapsed or Refractory Epstein-Barr Virus-Positive Peripheral T-Cell Lymphoma	16/04
Viracta Therapeutics Announces Positive Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial in Patients with Relapsed or Refractory Epstein-Barr Virus-Positive (EBV+) Peripheral T-Cell Lymphoma	15/04
Viracta Therapeutics, Inc. Reports Positive Topline Results from Stage 1 of the Pivotal Phase 2 NAVAL-1 Trial	15/04
Viracta Therapeutics : HST 2024 – Presentation	15/04
Viracta Therapeutics to Present Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial at the 2024 Annual Congress of The Hematology Society of Taiwan	01/04
Viracta Therapeutics to Present Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial at the 2024 Annual Congress of The Hematology Society of Taiwan	01/04
Lenz Therapeutics, Graphite Bio Complete Merger; Combined Company Names New CFO	21/03
Viracta Therapeutics, Inc. Announces Executive Changes	20/03
Viracta Therapeutics, Inc. Announces Chief Financial Officer Changes	20/03

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Viracta Therapeutics, Inc.

Aandelen

VIRX

US92765F1084

Andere talen

Filters